CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) --

马萨诸塞州剑桥，2026年8月4日（环球电讯社）--

CAMP4 Therapeutics Corporation

CAMP4治疗公司

('CAMP4' or 'the Company') (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional and accredited investors..

CAMP4（或称“公司”）（纳斯达克股票代码：CAMP）是一家处于临床阶段的生物制药公司，正在开发一系列靶向调控性RNA的治疗产品，旨在上调基因表达，以恢复健康的蛋白质水平，从而治疗多种遗传性疾病。该公司今日宣布，根据其与某些机构投资者和认可投资者于2025年9月9日签署的证券购买协议，已完成此前宣布的私募配售的第二期交割。

In connection with the second closing, the Company received approximately $50.1 million in gross proceeds in exchange for 10,756,498 shares of common stock priced at $1.53 per share of common stock, 39,306 shares of common stock priced at $1.65 to certain directors, employees and consultants of the Company, and 21,925,368 pre-funded warrants in lieu of common stock for $1.5299 for each pre-funded warrant sold in lieu of common stock.

在第二次交割中，公司获得了约5,010万美元的总收益，以换取以下证券：10,756,498股普通股，每股价格为1.53美元；向公司某些董事、员工和顾问发行的39,306股普通股，每股价格为1.65美元；以及21,925,368份预付认股权证，用于替代普通股，每份替代普通股的预付认股权证售价为1.5299美元。

The Company intends to use the net proceeds from the private placement to support the continued advancement of CMP-002, for which the Company recently announced it had received clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial in SYNGAP1-related disorder, as well as to support the continued development of the Company’s early-stage pipeline..

本公司拟将私募发行的净收益用于支持CMP-002的持续研发进展。该公司最近宣布，已获得澳大利亚治疗商品管理局及当地人类研究伦理委员会的批准，启动针对SYNGAP1相关疾病的1/2期临床试验。此外，净收益还将用于支持公司早期研发管线的持续发展。

Investors that participated in the second closing include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1.

参与第二轮交割的投资者包括 Coastlands Capital、Janus Henderson Investors、Balyasny Asset Management、Vivo Capital、5AM Ventures、Adage Capital Management LP、Trails Edge Capital Partners 以及 CURE SYNGAP1。

Leerink Partners acted as lead placement agent in connection with the second closing. Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acted as co-placement agents.

Leerink Partners 在第二次交割中担任牵头配售代理。Piper Sandler & Co.、Cantor Fitzgerald & Co. 和 Wedbush Securities Inc. 担任联合配售代理。

The securities offered in the private placement, including the shares underlying the pre-funded warrants, were sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or under any applicable state securities laws.

本次私募发行的证券，包括预融资权证所对应的标的股份，系在不涉及公开发行的交易中出售，且未根据经修订的《1933年证券法》（以下简称“《证券法》”）或任何适用的州证券法律进行注册。

Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The investors have been granted customary resale registration rights for the shares of common stock issuable upon exercise of the pre-funded warrants issued to them in the financing..

因此，除非依据有效的注册声明或适用《证券法》及适用的州证券法律中关于注册要求的豁免，否则不得在美国重新要约或转售该等证券。投资者已就因行使向其发行的预融资权证而可发行的普通股股份，获授予惯常的转售注册权。

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the securities described herein, nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction..

本新闻稿不构成出售或征求购买本文所述证券的要约，也不得在根据该司法管辖区的证券法进行注册或资格认定之前，在任何此类要约、征求或销售行为属违法的司法管辖区内出售此类证券。

For further information, please see the Company’s current report on Form 8-K to be filed with the SEC.

欲了解更多信息，请参阅公司将向美国证券交易委员会（SEC）提交的8-K表格当前报告。

About SYNGAP1-Related Disorder

关于SYNGAP1相关疾病

SYNGAP1-related disorder (also referred to as SYNGAP1) is a rare, haploinsufficient CNS disorder caused by mutations in the SYNGAP1 gene, resulting in approximately 50% of normal SYNGAP protein levels. The condition affects over 10,000 individuals in the United States and is characterized by intellectual disability in 100% of patients, epilepsy in approximately 85%, severe behavioral problems in approximately 70%, sleep problems in approximately 60%, and limited communication, with approximately 30% of patients being non-verbal.

SYNGAP1相关障碍（也称为SYNGAP1）是一种罕见的、由单倍剂量不足引起的中枢神经系统疾病，由SYNGAP1基因突变导致，使正常的SYNGAP蛋白水平降至约50%。该病在美国影响超过10,000人，其特征为：100%的患者存在智力障碍，约85%的患者患有癫痫，约70%的患者有严重行为问题，约60%的患者存在睡眠问题，以及沟通能力受限，其中约30%的患者无语言能力。

There are currently no approved disease-modifying therapies for patients living with SYNGAP1..

目前尚无针对SYNGAP1相关疾病患者的获批疾病修饰疗法。

About CMP-002

关于 CMP-002

CMP-002 is CAMP4's lead investigational antisense oligonucleotide (ASO) therapeutic candidate designed to bind to a SYNGAP1-specific regRNA to increase SYNGAP1 gene expression and restore SYNGAP protein toward near wild-type levels. Administered intrathecally, CMP-002 has demonstrated dose-dependent increases in SYNGAP protein expression in patient-derived neurons, reversal of disease-relevant behavioral phenotypes in a humanized haploinsufficient mouse model, statistically significant improvement of seizure phenotypes and parameters in a chemically induced seizure mouse model, and broad brain distribution with significant SYNGAP protein upregulation in non-human primates..

CMP-002 是 CAMP4 公司领先的在研反义寡核苷酸（ASO）治疗候选药物，旨在结合 SYNGAP1 特异性调控 RNA（regRNA），以提高 SYNGAP1 基因表达，并使 SYNGAP 蛋白水平恢复至接近野生型水平。通过鞘内给药，CMP-002 在患者来源的神经元中表现出剂量依赖性的 SYNGAP 蛋白表达增加；在人源化单倍剂量不足小鼠模型中逆转了与疾病相关的行为表型；在化学诱导癫痫小鼠模型中显著改善了癫痫表型和参数（具有统计学意义）；并且在非人灵长类动物中显示出广泛的脑部分布以及显著的 SYNGAP 蛋白上调。

About CAMP4 Therapeutics

关于CAMP4 Therapeutics

CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression.

CAMP4 正在开发针对多种遗传疾病的疾病修饰疗法，在这些疾病中，增加健康蛋白质的表达可能带来治疗益处。我们的方法通过利用基因调控的基本机制来扩增 mRNA。为了扩增 mRNA，我们的治疗性反义寡核苷酸（ASO）候选药物靶向调控 RNA（regRNAs），这些 RNA 在局部作用于转录因子，是基因表达的主要调控因子。

CAMP4's proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful..

CAMP4 专有的 RAP Platform® 能够实现调控 RNA（regRNAs）的图谱绘制，并生成旨在靶向与单倍剂量不足和隐性部分功能丧失疾病相关基因关联的 regRNAs 的治疗候选药物；此类疾病超过 1,200 种，其中蛋白质表达的适度提升可能具有临床意义。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements.

本新闻稿包含前瞻性陈述，这些陈述涉及风险、不确定性和偶然事件，其中许多超出本公司的控制范围，可能导致实际结果、表现或成就与预期结果、表现或成就存在重大差异。除本新闻稿中包含的历史事实陈述外，所有陈述均为前瞻性陈述。

In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

在某些情况下，您可以通过“可能”、“将”、“应当”、“预期”、“计划”、“预计”、“能够”、“打算”、“目标”、“规划”、“考虑”、“相信”、“估计”、“预测”、“潜在”或“继续”等术语，或其否定形式或其他类似表述来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements include, but are not limited to, statements regarding the Company’s planned use of proceeds from the private placement; the initiation, timing, conduct, and advancement of CMP-002 into a clinical trial; the potential therapeutic benefits of CMP-002; the Company’s regulatory, clinical and development plans; and the satisfaction of closing conditions.

前瞻性陈述包括但不限于以下方面的陈述：公司计划使用私募配售所得资金的用途；CMP-002 临床试验的启动、时间安排、实施及推进；CMP-002 的潜在治疗益处；公司的监管、临床和开发计划；以及交割条件的满足。

The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the uncertainty of preclinical and clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company's current pro.

本新闻稿中的前瞻性陈述仅截至本新闻稿发布之日有效，并受多种已知和未知风险、不确定性和假设的影响，这些因素可能导致公司的实际结果与前瞻性陈述中预期的结果存在重大差异，包括但不限于：临床前和临床开发的不确定性，该过程漫长且昂贵，且结果具有不确定性；以及与公司当前产品在开发和商业化过程中可能产生的额外成本或延误，或未能完成开发和商业化的相关风险。

Contacts

联系人

Investor Relations:

投资者关系：

Sara Michelmore

萨拉·米歇尔莫尔

Milestone Advisors

里程碑顾问

sara@milestone-advisorsllc.com

sara@milestone-advisorsllc.com

Media:

媒体：

Sofia Bermudez

索菲亚·贝尔穆德斯

LifeSci Communications

生命科学传播

sbermudez@lifescicomms.com

sbermudez@lifescicomms.com